文档介绍：Advances in AML/MDS: The Role of Multicenter Clinical Trials
Dennis L. Confer, MD
Chief Medical Officer, NMDP
About These Slides
Our thanks to the presenters who gave permission to include their original data
Users are encouraged to use these slides in their own mercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent
These slides may not be published or posted online without permission from Clinical Care Options
Disclaimer The materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or panies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
3
Annual Numbers of Blood and Marrow Transplantations, 1970-2006 - Worldwide -
Number of Transplants
4
Current Annual Activity Estimates – Worldwide –
Autologous transplants ~40,000 annually
Allogeneic transplants ~25,000 annually
More than half of allogeneic transplants use unrelated donor products
More than 14 million adult donors are registered worldwide
The world’s inventory of unrelated donor (., public) umbilical cord blood units exceeds 400,000
5
National Marrow Donor Program Adult Donors & Cord Blood Units – Oct, 2009
Adult Donors
8,013,658
CBUs 114,500
6
NMDP Transplants Facilitated by Fiscal Year 1987–2009
Cord blood
Peripheral blood stem cells
Bone marrow
7
NMDP Minority Transplants by FY 2007–2009
Cord blood
Adult donors
20%
28%
34%
3%
23%
14%
191
364
244
438
328
450
8
NMDP Transplant Recipients by Diagnosis – Selected Malignancies
9
NMDP Transplant Reci